- Report
- June 2025
- 400 Pages
Global
From €4505EUR$4,949USD£3,881GBP
- Report
- July 2024
- 200 Pages
Global
From €4505EUR$4,949USD£3,881GBP
- Report
- February 2024
- 140 Pages
Global
From €4523EUR$4,969USD£3,897GBP
- Report
- April 2023
- 147 Pages
Global
From €4505EUR$4,949USD£3,881GBP
- Report
- April 2023
- 147 Pages
Global
From €4505EUR$4,949USD£3,881GBP
- Report
- April 2023
- 147 Pages
Global
From €4505EUR$4,949USD£3,881GBP
- Report
- May 2024
- 139 Pages
Global
From €3640EUR$3,999USD£3,136GBP
- Report
- May 2024
- 134 Pages
Global
From €3640EUR$3,999USD£3,136GBP
- Report
- April 2023
- 115 Pages
Global
From €4324EUR$4,750USD£3,725GBP
- Report
- June 2022
- 120 Pages
Global
From €4324EUR$4,750USD£3,725GBP
- Report
- July 2024
- 185 Pages
Global
From €2276EUR$2,500USD£1,961GBP
- Report
- May 2024
- 174 Pages
Global
From €2276EUR$2,500USD£1,961GBP
- Report
- July 2024
- 200 Pages
Global
From €4505EUR$4,949USD£3,881GBP
- Report
- June 2025
- 101 Pages
Global
From €16380EUR$17,995USD£14,113GBP
- Report
- February 2023
- 48 Pages
Global
From €3636EUR$3,995USD£3,133GBP
- Report
- June 2024
- 200 Pages
Global
From €4547EUR$4,995USD£3,918GBP
- Report
- November 2024
- 150 Pages
Global
From €4415EUR$4,850USD£3,804GBP
- Report
- October 2021
- 288 Pages
Global
From €3277EUR$3,600USD£2,823GBP
- Report
- May 2022
- 70 Pages
Global
From €2276EUR$2,500USD£1,961GBP
- Report
- May 2025
- 99 Pages
Global
From €3500EUR$4,119USD£3,121GBP

The Anti Tumour Necrosis Factor (anti-TNF) market is a subset of the Immune Disorders Drugs market. Anti-TNF drugs are used to treat a variety of immune-mediated diseases, such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. These drugs work by blocking the action of TNF, a protein that is involved in inflammation and tissue destruction. Anti-TNF drugs are generally administered as injections or infusions, and are often used in combination with other medications.
The anti-TNF market is highly competitive, with a number of companies offering products. These include AbbVie, Amgen, Janssen, Merck, Pfizer, and UCB. Each company has its own portfolio of anti-TNF drugs, and they are continually developing new products to meet the needs of patients. Show Less Read more